Health
Rapid generation of divergent synthetic antibodies against SARS-CoV-2 in a cell-free engineering platform – News-Medical.Net
In a groundbreaking bioRxiv paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute…
In a groundbreaking bioRxiv* paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute in the US engineered antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein by using a novel approach. In doing so, they also identified more than 800 predicted binder families.
The ongoing coronavirus disease (COVID-19) pandemic is caused by the SARS-CoV-2,…
-
Noosa News23 hours agoBrisbane vs Collingwood live blog: Richmond selects Noah Balta as unbeaten Lions prepare for Magpies test
-
General24 hours agoCanberra man named as doctor accused of rape after suppression order lifted
-
General22 hours agoNT Coalition candidate Lisa Siebert diverges from Jacinta Nampijinpa Price on royal commission call
-
General23 hours agoPlea for help so the music doesn’t stop for Bluesfest